Ruby Hsu earned her BA from Harvard University and her PhD in Neurobiology from Columbia University, before completing postdoctoral studies at the University of California San Francisco. She joined Advanced Cell Diagnostics (now a Bio-Techne company) as an early employee and served as the commercial and operational leader of the CRO business prior to becoming Director of Business Development. She is now Director of Biopharma Partnerships at PathAI, a leader in the development and application of artificial intelligence for computational pathology.
AI and Data Science Showcase:
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
AI-Powered Pathology for Prospective Clinical Trials
Learn about PathAI's clinical trial and drug development tools powered by AI digital pathology, including new advancements in immunophenotyping and molecular predictions.
The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.